Sertraline-induced pseudocholinesterase enzyme deficiency by Zencirci, Beyazit
© 2010 Zencirci, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of General Medicine 2010:3 375–378
International Journal of General Medicine Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
375
CAse rePOrT
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/IJGM.S14365
sertraline-induced pseudocholinesterase enzyme 
deficiency
Beyazit Zencirci
MOsTAs Private Health Hospital, 
Department of Anesthesiology, 
Kahramanmaras, Turkey
Correspondence: Beyazit Zencirci 
M. Akif Inan Mah. Alparslan Turkes 
Bulvari, seyhan Apt. No: 209 D: 5, 
Merkez-Kahramanmaras, Turkey 
Tel +90 344-2258300 
Fax +90 344-2258303 
email bzencirci@fastmail.fm
Abstract: A 47-year-old Turkish male was scheduled for laparoscopic cholecystectomy under 
general anesthesia. The patient had 2 operations 28 and 19 years ago under general anesthesia. 
It was learned that the patient was administered succinylcholine during both of these previous 
operations and that he did not have a history of prolonged recovery or postoperative apnea. The 
patient had been using sertraline for 3 years before the operation. Pseudocholinesterase is a 
drug-metabolizing enzyme responsible for hydrolysis of the muscle-relaxant drugs mivacurium 
and succinylcholine. Deficiency of this enzyme from any cause can lead to prolonged apnea 
and paralysis following administration of mivacurium and succinylcholine. The diagnosis 
of pseudocholinesterase enzyme deficiency can be made after careful clinic supervision and 
peripheral nerve stimulator monitoring. A decrease in the activity of pseudocholinesterase 
enzyme and a decline in the block effect over time will help verify the diagnosis. Our patient’s 
plasma cholinesterase was found to have low activity. Instead of pharmacological interventions 
that may further complicate the situation in such cases, the preferred course of action should 
be to wait until the block effect declines with the help of sedation and mechanical ventilation. 
In our case, the prolonged block deteriorated in the course of time before any complications 
developed.
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Introduction
Pseudocholinesterase (PCHE) is an enzyme with a complex molecular structure.1 It is 
synthesized in the liver and immediately released into the plasma.2 The plasma half-life 
has been estimated to be approximately 12 days.3 Deficiency or reduced activity of this 
enzyme results in significant prolongation of mivacurium- or succinylcholine-induced 
neuromuscular blockade.4 In addition, a number of disease states or concomitant drug 
administration may reduce PCHE activity.
Mivacurium, which is a nondepolarizing neuromuscular blocking drug administered 
in doses of 0.1 to 0.2 mg/kg, also produces rapid onset of neuromuscular blockade 
lasting for 15 to 30 minutes.5 The rapid ester hydrolysis of mivacurium by PCHE 
results in the short duration of action of this drug, which is ideal for providing muscle 
relaxation for brief surgical procedures.6 But the duration of mivacurium of action in 
adults is inversely related to serum PCHE activity.7,8
Sertraline is an antidepressant and antipanic agent that is a potent and selective 
inhibitor of serotonin reuptake into the presynaptic terminals. It has relatively weak 
effects on the cytochrome P450 system, a tolerability profile that is positive compared 
with antidepressants of other classes, and it is relatively safe in overdose. These   findings International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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contribute to sertraline being the first-line agent for the 
treatment of several psychiatric disorders.9 It was shown, 
however, that sertraline and other antidepressants inhibited 
acetylthiocholine hydrolysis by cholinesterases in human 
serum and erythrocyte membrane.10
In this article, we share our experience of a case with 
acquired pseudocholinesterase enzyme deficiency due to 
sertraline use, and provide a literature review.
Case report*
A 47-year-old Turkish male, 83 kg in weight and 175 cm in 
height, was scheduled for laparoscopic cholecystectomy (due 
to cholecystitis with an acute stone) under general anesthesia. 
Under general anesthesia, the case had an appendectomy 
28 years ago and a right inguinal hernia operation 19 years 
ago. It was learned that the patient was administered suc-
cinylcholine during both these operations and that he did 
not have a history of prolonged recovery or postoperative 
apnea. Except for alkaline phosphatase (ALP) (176 U/L), 
alanine aminotransferase (ALT) (52 U/L) and a minimal 
increase in aspartate aminotransferase (AST) (61 U/L), and 
a slight leucocytosis (9.8 × 109/L), no other pathologies were 
identified during preoperative laboratory investigation. The 
patient had been using sertraline (100 mg/day) for 3 years 
for major depressive disorder.
Following preoxygenation, induction of anesthesia was 
achieved with 200 mg of propofol. Tracheal intubation 
was achieved with 17 mg of mivacurium. Isoflurane was 
used as the general anesthetic inhalation agent. The operation 
lasted for 30 minutes and the surgery was uneventful. After 
surgery, the inhalation agent was discontinued, the patient 
received 100% oxygen but there was no clinical evidence of 
neuromuscular function recovery and there was no response 
to train-of-four stimulation. Peripheral nerve stimulator 
(PNS) produced zero twitches. Anesthesia was therefore 
maintained with 0.5% isoflurane in 50% nitrous oxide 
and oxygen because there was no evidence of improved 
neuromuscular function 50 minutes after administration 
of mivacurium. All vital signs were stable, and oxygen 
saturation remained 100%. After an additional 20 minutes, 
a PCHE deficiency was suspected. Five milligrams of 
midazolam was administered intravenously for its seda-
tive and amnestic effects. Later the patient was transferred 
to the Post-anesthesia Care Unit (PACU) for observation 
and ventilator support. Spontaneous muscle twitching was 
noted 2 hours and 20 minutes later. Train-of-four response 
ratio was 75% 2 hours and 55 minutes after mivacurium 
administration.
The patient regained sufficient motor function to meet 
extubation requirements 3 hours and 15 minutes after the 
initial use of mivacurium. Midazolam infusion was dis-
continued and clinical assessment confirmed recovery of 
neuromuscular function. The patient was extubated for 
205 minutes following the administration of mivacurium 
and further recovery was uneventful. Plasma cholinesterase 
was found to have very low activity (788 IU/L). The patient 
was transferred to a hospital ward for the evening and was 
discharged 4 days later.
Discussion
Mivacurium is a potent benzylisoquinoline, nondepolarizing, 
neuromuscular blocking drug. A recommended intravenous 
dose of 0.15 to 0.2 mg/kg provides tracheal intubating con-
ditions within 2 to 2.5 minutes, with a predicted duration of 
action of 15 to 25 minutes, making it an ideal drug for short 
procedures requiring tracheal intubation.11 It is a structural 
relative of atracurium, but it does not undergo Hofmann 
elimination and is rapidly hydrolyzed by PCHE. The activity 
of PCHE affects its duration of action.4
PCHE is a tetrameric glycoprotein enzyme produced by 
the liver, which hydrolyzes choline esters such as those found 
in succinylcholine, mivacurium, procaine, chloroprocaine, 
tetracaine, cocaine, and heroine.12 In patients with a normal 
genotype for PCHE, mivacurium’s duration of action is 
inversely related to PCHE activity and duration of action is 
slightly prolonged if activity is low.13
When there is a deficiency of this enzyme due to the 
presence of one or more atypical alleles, mivacurium is not 
properly metabolized and thus muscle paralysis can last 
for several hours. There are 2 forms of inherited atypical 
pseudocholinesterase deficiency. The heterozygous atypical 
form affects from 1 in 25, to 1 in 480 individuals (depending 
on the severity of the condition).12 Patients heterozygous for 
an abnormal enzyme may show up to 50% prolongation of 
block.13 In patients homozygous for an abnormal enzyme, 
duration may be significantly prolonged, and even a small 
dose (eg, 0.03 mg/kg) can result in complete paralysis for 
up to 128 minutes.14 There are now several case reports in 
the literature of prolonged block following mivacurium 
administration.
Different disease states and/or drug administrations 
may affect PCHE activity. Physiological reductions may 
*Monitoring included electrocardiography (ECG), noninvasive arterial 
blood pressure (NIBP), oxygen saturation (SpO2), capnography (ETCO2), 
and peripheral nerve stimulator (PNS) monitoring applied over the ulnar 
nerve in this case.International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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occur with extremes of age and during pregnancy.15 Other 
acquired causes of decreased activity include renal and liver 
disease, malignancy, burns, chronic debilitation/malnutrition, 
myocardial infarction/cardiac failure, collagen diseases, 
myxedema, and organophosphate poisoning.16 Plasma 
cholinesterase levels in human subjects with protein energy 
malnutrition have been investigated.17
Drugs that inhibit the enzyme’s activity include ace-
tylcholinesterase inhibitors (neostigmine, pyridostigmine, 
physostigmine, and edrophonium), anticholinesterases (espe-
cially echothlophate), cytotoxic agents (such as cyclophosph-
amide), steroids, ester-type local anesthetics, hexafluorenium, 
pancuronium, and oral contraceptives.18
Our patient previously had 2 operations under general 
anesthesia with succinylcholine. However, a prolonged 
apnea and low enzyme activity (788 IU/L) was present in 
the operation reported here. Although the patient had not had 
any problems during the previous operations, absence of a 
medical history proving the existence of the same problem 
in close relatives led us to think that this was an acquired 
PCHE deficiency. At this stage, we at once started to imple-
ment an algorithm which is usually used in cases of PCHE 
deficiency. At this stage, we also started to examine the 
causes of acquired PCHE deficiency thoroughly. However, 
we noted that the medical conditions (such as extremes 
of age, pregnancy) and problems (such as renal and liver 
disease, malnutrition) reported in the literature that we have 
tried to summarize above did not match our case. Therefore, 
we considered the drugs known to affect PCHE activity that 
the patient may have been taking. We discovered that the 
patient had been using sertraline (100 mg/day) for 3 years 
due to depression.
Sertraline is a serotonin reuptake inhibitor (SSRI) that is 
indicated for the treatment of depression. With therapeutic 
doses, side effects are minimal. Sertraline has a wide thera-
peutic index and appears to be safer than the tricyclic anti-
depressants in overdose.19 The usual clinical antidepressants 
(fluoxetine, sertraline, and amitriptyline) are, however, inhibi-
tors of the cholinesterases in human serum and erythrocyte 
membrane. Antidepressants exhibit this inhibiting effect by 
reversibly attaching to the enzyme’s bottom of the active site 
gorge, and the collapse of the product (eg, mivacurium or 
succinylcholine) being hydrolyzed by the enzyme decreases 
during this process of attachment.10 The order of inhibitory 
potency was sertraline . amitriptyline .. fluoxetine. The 
concentrations of antidepressants necessary to inhibit serum 
cholinesterase are relatively close to the clinical levels found 
after pharmacological use of sertraline and amitriptyline. 
Consequently, undesirable pharmacological and toxicological 
side effects of these antidepressants can be related, at least in 
part, to inhibition of serum and erythrocyte cholinesterases.10 
Therefore, chronic enzyme inhibition which might have 
developed due to 3 years of use of sertraline in our patient 
led to a significant and marked prolongation in the activity 
time of the neuromuscular blocking agent metabolized by 
this enzyme.
The results achieved by Müller et al10 corroborated our 
suspicions about sertraline. Also, the retested (3 months after 
the operation) PCHE value (2762 IU/L) was seen to have 
returned to normal after the patient gave up using sertraline 
under the supervision of a psychiatrist. We did not discover 
any case that implied an interaction between sertraline and 
pseudocholinesterase in our literature review, and we believe 
this is the first presentation of such a case.
When we understood that we were dealing with a case 
of acquired PCHE deficiency, we made our treatment plan. 
Our main aim was to administer a supportive treatment to the 
patient until enzyme activity returned to normal. Therefore 
we did not consider a blood transfusion (considering the risks 
of blood transfusion, such as allergic reactions, infection, 
fever reaction). We also avoided administering drugs (such 
as calcium, neostigmine) that might complicate the pres-
ent condition. The clinician should be especially aware 
that administering neostigmine to a patient with prolonged 
mivacurium-induced block will inhibit plasma cholinesterase 
activity. Therefore, blood should not be drawn for cholinest-
erase activity until the effect of neostigmine dissipates. In 
our case, when we suspected PCHE deficiency, together with 
PNS findings, we sent the blood samples to the laboratory for 
enzyme analysis. Consequently, we supported our case solely 
with sedation, mechanical ventilation, and PNS monitoring, 
and without neostigmine application.
Conclusion
Prolonged blocks may be encountered as a result of PCHE 
enzyme deficiency when mivacurium is used. In our case, 
this situation was due to sertraline, which is commonly 
administered for various psychiatric disorders, particularly 
depression.
In this context, we believe two issues should be high-
lighted. Firstly, while examining the drugs used by patients 
during preoperative anesthesia anamnesis, next-generation 
antidepressants (especially SSRIs) should not be ignored. As 
in the case reported, this group of drugs, known to have a 
wide safety margin, may cause casual and unexpected block 
prolongation when used along with drugs (mivacurium and International Journal of General Medicine
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succinylcholine) that are hydrolyzed especially by PCHE 
activity during anesthesia.
Secondly, in these situations, attempted reversal of the 
block was at best only partially successful, and the patients 
were partially paralyzed and minimally sedated while 
attempts were made to have them breathe – a very unpleas-
ant   experience. In cases of prolonged block, no reversal was 
attempted. The patients were kept sedated, and their lungs 
mechanically ventilated until the block recovered spontane-
ously, and then extubated without problem.
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